| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H15NO3S |
| Molecular Weight | 217.285 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CS)C(=O)N1CCC[C@H]1C(O)=O
InChI
InChIKey=FAKRSMQSSFJEIM-BQBZGAKWSA-N
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7-/m0/s1
| Molecular Formula | C9H15NO3S |
| Molecular Weight | 217.285 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Epicaptopril is an impurity of Captopril, which is an orally active angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure. Epicaptopril does not show any inhibition of angiotensin-converting enzyme (ACE), and can be used as negative control in ACE inhibition experiments
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
The protective effects of SH-ACEIs from free radical-induced cell damage have been also assessed in cultured endothelial cells exposed to a superoxide anion and hydroxyl radicals generating system. Preincubation of the cells with captopril, epicaptopril, or zofenopril produced a concentration-dependent (10–200 mkM) inhibition of malonyldialdehyde formation. Both loss of cell viability and membrane blebbing were reduced by SH-ACEIs at concentrations as low as 10 mkM. In contrast, lisinopril and enalaprilat at concentrations up to 200 mkM were ineffective
